Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients

Autor: Seker, M. M., Sancaktar, E., Acibucu, D. O., Filiz, A. K., Deveci, K., Bahceci, A., Kacan, T., Babacan, N., Yuce, S.
Přispěvatelé: [Seker, M. M. -- Bahceci, A. -- Kacan, T. -- Babacan, N.] Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- [Sancaktar, E. -- Acibucu, D. O. -- Deveci, K.] Cumhuriyet Univ, Fac Med, Dept Biochem, Sivas, Turkey -- [Filiz, A. K.] Cumhuriyet Univ, Fac Med, Dept Physiol, Sivas, Turkey -- [Yuce, S.] Cumhuriyet Univ, Fac Med, Dept Ear & Nose & Throat, Sivas, Turkey, Sancaktar, Erol -- 0000-0003-0165-587X
Jazyk: angličtina
Rok vydání: 2013
Předmět:
ISSN: 0003-2808
Popis: WOS: 000328084800015
PubMed ID: 24254563
BACKGROUND: Angiogenesis is a very essential process in tumor biology. Vascular endothelial growth factor (VEGF), angiopoietin and its receptor (TIE-2) are very important mediators for angiogenesis. In this trial, we aimed to analyze the role of these mediators on chemotherapy response and survival. PATIENTS AND METHODS: Forty four cancer patients and 22 healthy controls were included in the study. Baseline serum samples were obtained from all participants and post-chemotherapy serum samples were obtained from the cancer patients. Serum vascular endothelial growth factor and TIE-2 levels were measured with quantitative enzyme-linked immunosorbent assay techniques. RESULTS: The baseline serum vascular endothelial growth factor level was 187.5 and 120.2 pg/ml in cancer patients and the control group (p = 0.006). The baseline serum TIE-2 level was 615.9 and 242.5 pg/ml in the patients and control group (p < 0.001). There was a significant difference between patients' baseline and post-chemotherapy VEGF levels (111.9 pg/ml; p < 0.001) and patients' baseline and post-chemotherapy TIE-2 levels (344.5 pg/ml; p < 0.001). The overall survival rate was better in patients who had lower baseline VEGF and TIE-2 levels and whose TIE-2 level had decreased with chemotherapy. CONCLUSIONS: Higher baseline TIE-2 and VEGF levels are related and worsen survival. Decreasing levels of TIE-2, but not VEGF, which, with chemotherapy, may be predictive for survival.
Databáze: OpenAIRE
Externí odkaz: